Solid Biosciences (SLDB) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free SLDB Stock Alerts $8.26 +0.62 (+8.12%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 6:34 AM | americanbankingnews.comPiper Sandler Initiates Coverage on Solid Biosciences (NASDAQ:SLDB)June 1 at 6:34 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Price Target Cut to $10.00May 31 at 2:14 PM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Given New $10.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. dropped their target price on shares of Solid Biosciences from $12.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday.May 31 at 9:06 AM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Coverage Initiated at Piper SandlerPiper Sandler assumed coverage on Solid Biosciences in a research report on Friday. They set an "overweight" rating and a $20.00 target price for the company.May 25, 2024 | americanbankingnews.comOKYO Pharma (NASDAQ:OKYO) & Solid Biosciences (NASDAQ:SLDB) Head to Head ComparisonMay 23, 2024 | americanbankingnews.comBrokers Set Expectations for Solid Biosciences Inc.'s Q2 2024 Earnings (NASDAQ:SLDB)May 22, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Solid Biosciences Inc. (NASDAQ:SLDB) Issued By HC WainwrightSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Solid Biosciences in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst A. He now forecasts thaMay 20, 2024 | markets.businessinsider.comBuy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical ProspectsMay 20, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Monday.May 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 17, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Solid Biosciences Inc. Issued By William Blair (NASDAQ:SLDB)Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Investment analysts at William Blair raised their Q3 2024 earnings per share estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, May 15th. William Blair analyst T. Lugo now forecasts thatMay 17, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by BrokeragesShares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objectivMay 16, 2024 | marketbeat.comBarclays Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $18.00Barclays decreased their target price on shares of Solid Biosciences from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday.May 15, 2024 | msn.comSolid Biosciences reports Q1 resultsMay 15, 2024 | investorplace.comSLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024May 15, 2024 | globenewswire.comSolid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsMay 2, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest Up 49.8% in MarchSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 920,900 shares, a growth of 49.8% from the March 15th total of 614,900 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 362,300 shares, the days-to-cover ratio is presently 2.5 days.April 10, 2024 | seekingalpha.comBuy Solid Biosciences: Unpacking Its Main Value DriverApril 3, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comSolid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003April 1, 2024 | globenewswire.comSolid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003March 28, 2024 | msn.comWilliam Blair starts Solid Biosciences at outperformMarch 28, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by AnalystsSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objectiMarch 28, 2024 | marketbeat.comSolid Biosciences' (SLDB) Outperform Rating Reaffirmed at William BlairWilliam Blair restated an "outperform" rating on shares of Solid Biosciences in a research report on Thursday.March 27, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Reaches New 1-Year High at $14.99Solid Biosciences (NASDAQ:SLDB) Sets New 1-Year High at $14.99March 27, 2024 | finance.yahoo.comSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumMarch 24, 2024 | finance.yahoo.comSLDB Apr 2024 7.500 putMarch 19, 2024 | markets.businessinsider.comCautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid BiosciencesMarch 18, 2024 | marketbeat.comBarclays Increases Solid Biosciences (NASDAQ:SLDB) Price Target to $21.00Barclays raised their target price on Solid Biosciences from $8.00 to $21.00 and gave the company an "overweight" rating in a report on Monday.March 18, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Thursday.March 18, 2024 | markets.businessinsider.comSolid Biosciences (SLDB) Gets a Buy from BarclaysMarch 16, 2024 | finance.yahoo.comSLDB Sep 2024 17.500 callMarch 15, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives New Coverage from Analysts at CitigroupCitigroup started coverage on Solid Biosciences in a research note on Friday. They set a "buy" rating and a $16.00 price objective on the stock.March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial StabilityMarch 14, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Upgraded to Overweight at Piper SandlerPiper Sandler upgraded Solid Biosciences from a "neutral" rating to an "overweight" rating and raised their target price for the company from $8.00 to $20.00 in a research report on Thursday.March 13, 2024 | finanznachrichten.deSolid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsMarch 13, 2024 | markets.businessinsider.comSolid Biosciences Stock Drops 4% Due To Wider Loss In Q4March 13, 2024 | msn.comSolid Biosciences, Cue Biopharma, Annexon among healthcare moversMarch 13, 2024 | globenewswire.comSolid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsMarch 11, 2024 | realmoney.thestreet.comSolid Biosciences price target raised by $7 at H.C. Wainwright, here's whyMarch 11, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)March 7, 2024 | msn.comSolid Biosciences signs agreement with Armatus Bio for AAV-SLB101March 7, 2024 | finance.yahoo.comSolid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDMarch 1, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 607,300 shares, a growth of 41.8% from the January 31st total of 428,300 shares. Currently, 2.0% of the company's shares are sold short. Based on an average daily volume of 475,200 shares, the short-interest ratio is presently 1.3 days.February 22, 2024 | benzinga.comSolid Biosciences Stock (NASDAQ:SLDB) Insider TradesFebruary 22, 2024 | benzinga.comSolid Biosciences Stock (NASDAQ:SLDB), Short Interest ReportFebruary 18, 2024 | msn.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 17, 2024 | finance.yahoo.comSLDB Mar 2024 10.000 putFebruary 6, 2024 | markets.businessinsider.comHold Rating on Solid Biosciences Amid Gene Therapy Developments and Regulatory Milestones Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. SLDB Media Mentions By Week SLDB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLDB News Sentiment▼0.400.75▲Average Medical News Sentiment SLDB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLDB Articles This Week▼71▲SLDB Articles Average Week Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Shattuck Labs News Today Immutep News Today Acrivon Therapeutics News Today Corbus Pharmaceuticals News Today ProQR Therapeutics News Today Celcuity News Today BeyondSpring News Today vTv Therapeutics News Today Assembly Biosciences News Today Champions Oncology News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLDB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
